GUIDELINE DEVELOPMENT PROCESS, EVIDENCE GRADING, AND STAKEHOLDER AND PUBLIC CONSULTATION The Work Group consisted of a truly international group of kidney specialists, diabetologists, cardiologists, epidemiolo- gists, lipidologists, and a professional evidence review team. The Work Group formulated the scope of the guideline, and graded evidence on the basis of the GRADE (Grading of Recommendations Assessment, Development and Evalua- The guideline updates the 2003 Kidney Disease Outcomes Quality Initiative (K/DOQI) Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease.3 The evidence review team carried out systematic reviews for six topics of interest. Systematic searches were last conducted in August 2011 and supplemented with additional evidence through June 2013. Further guideline development, evidence synthesis, and writing of the guideline itself was carried out http://www.kidney-international.org review & 2014 International Society of Nephrology Correspondence: Christoph Wanner, Division of Nephrology, University Hospital Wu rzburg, Oberduerrbacherstrasse 6, Wu rzburg 9700, Germany. E-mail: wanner_c@ukw.de Members of the Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group were: Alan Cass, Amit X. Garg, Hallvard Holdaas, Alan G. Jardine, Lixin Jiang, Florian Kronenberg, Rulan S. Parekh, Tetsuo Shoji, and Robert J. Walker. Also see the Appendix. by the Work Group. Full details of the guideline development process, topic discussion, and consensus development can be found in the published guideline.1 The draft guideline was reviewed by the KDIGO Board of Directors, and revisions were incorporated before a structured, Internet-based public review process. Feedback from this process was reviewed by the Work Group, and final revisions were incorporated before publication of the guideline. The order of recommendations in the guideline was based on the order used in the 2003 K/DOQI publication, and it presents recommendations on assessment of lipid status before those related to treatment. 